Connor, Clark & Lunn Investment Management (CC&L)’s Niagen Bioscience NAGE Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.57M	Sell	582,448 -1,781	-0.3%	-$9.62K	0.01%	882
2025 Q4	$3.72M	Sell	584,229 -43,650	-7%	-$304K	0.01%	747
2025 Q3	$5.86M	Sell	627,879 -195,446	-24%	-$1.97M	0.02%	540
2025 Q2	$11.9M	Buy	823,325 +78,835	+11%	+$778K	0.04%	355
2025 Q1	$5.14M	Buy	744,490 +238,304	+47%	+$1.5M	0.02%	491
2024 Q4	$2.69M	Buy	506,186 +331,014	+189%	+$1.81M	0.01%	652
2024 Q3	$639K	Buy	175,172 +17,115	+11%	+$53.9K	﹤0.01%	1025
2024 Q2	$431K	Buy	158,057 +24,991	+19%	+$83.6K	﹤0.01%	1087
2024 Q1	$463K	Buy	133,066 +16,553	+14%	+$30.6K	﹤0.01%	1134
2023 Q4	$167K	Buy	116,513 +33,482	+40%	+$46.6K	﹤0.01%	1283
2023 Q3	$121K	Buy	83,031 +45,618	+122%	+$71.3K	﹤0.01%	1282
2023 Q2	$58.7K	Buy	+37,413	New	+$55.8K	﹤0.01%	1267

Other funds holding NAGE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s NAGE Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Niagen Bioscience (NAGE) stake by 0.3% in Q1 2026, selling an estimated $9.62K and leaving 582,448 shares worth $2.57M. The position accounts for 0.01% of the portfolio, ranked #882.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in NAGE in Q2 2023 and has held it in 12 quarters since. The position peaked at $11.9M in Q2 2025. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 582,448 shares of Niagen Bioscience worth $2.57M as of Q1 2026.
Connor, Clark & Lunn Investment Management (CC&L) sold 1,781 Niagen Bioscience shares in Q1 2026, an estimated $9.62K.
Niagen Bioscience made up 0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #882 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Niagen Bioscience in Q2 2023 and has held it in 12 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s Niagen Bioscience position peaked at $11.9M in Q2 2025.
143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.